Prices delayed by at least 15 minutes | Print
Aileron Therapeutics (ALRN)
Common SharesOpen
$3.8
Previous close
$3.76
Trade high
$4.01
Volume
86,944
Year high
$7.42
Year low
$1.01
Dividend yield
-
Market capitalisation
$65.62 mn
P/E ratio
-
ISIN
US00887A2042
This share can be held in a Dealing accountISALifetime ISAJISASIPP
Share price
Company profile
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development,LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.